LIDEX-E
LOE ApproachingNDATOPICALCREAM
Approved
Jun 1971
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 7h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LIDEX-E is a topical cream formulation approved in 1971 for dermatological indications. The specific mechanism of action and indication details are not currently available in standard references. This is a legacy small-molecule product with established clinical use.
LOE Approaching
As LOE approaches, commercial teams are likely small and focused on line extensions, partnerships, or market defense rather than growth.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
LIDEX-E offers minimal career growth opportunities as a legacy product in LOE phase with zero linked job openings. Roles available are primarily defensive, focused on managing decline or extending product life through formulation updates or market strategies rather than innovation or expansion.
Brand ManagerSales Representative
Worked on LIDEX-E at Alvogen? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.